Imperial Bioscience awarded grant for microneedle technology

Imperial Bioscience Ltd, a leading biopharmaceutical company, has been awarded a substantial grant under the Biomedical Catalyst 2023 Programme by Innovate UK. The grant award, totalling £0.5 million, will propel the further development of Imperial Bioscience’s Microneedle Patch Technology (MPT).

The company’s Microneedle Patch Technology has already made significant advancements in the cosmetic industry through the Luna Microcare product line. The technology is also said to hold great promise for a wide range of applications in the pharmaceutical sector, especially in the development of combination products.

Specifically, the grant enables Imperial Bioscience to apply its cutting-edge technology to the development of medicinal products. The project's primary goal is to complete the pre-clinical phase and transition into the clinical stage, focusing on addressing skin concerns such as acne management.

Innovate UK, a part of UK Research and Innovation, invests in innovation projects that aim to tackle significant health or healthcare challenges. It is a highly competitive funding program dedicated to assisting small and medium-sized enterprises (SMEs) in their research and development endeavours.

The chief executive of Imperial Bioscience, Dr Muhammet Avcil expressed his pleasure upon receiving the prestigious grant, emphasising the technology's tremendous potential in advancing drug delivery.

In particular, the "dissolving microstructure" developed, produced, and commercialised by Imperial Bioscience, aims to enhance drug delivery systems – which traditionally included orally administered medicines, injections, ointments, and patches - making them safer, more convenient, and more efficient in the delivery of active ingredients.

Dr Avcil looks forward to witnessing the future advancements that Imperial Bioscience will achieve in this field.

For more information visit, imperialbioscience.co.uk/awardedgrant-2023